GASTROINTESTINAL BLEEDING is a common medical condition. Incidence rates for upper gastrointestinal (UGI) bleeding vary from 50 to 150/100,000, 1-4 while rates for lower gastrointestinal (LGI) bleeding have not been well studied. 5 Over the past decade, advances in endoscopic technology have resulted in better characterization of the causes of gastrointestinal bleeding, and the ability to perform endoscopic therapy has revolutionized the approach to diagnosis and management. These improvements in diagnosis and treatment should be reflected in better outcomes, including a reduction in rebleeding rate, urgent surgical intervention, and mortality.
GASTROINTESTINAL BLEEDING is a common medical condition. Incidence rates for upper gastrointestinal (UGI) bleeding vary from 50 to 150/100,000, [1] [2] [3] [4] while rates for lower gastrointestinal (LGI) bleeding have not been well studied. 5 Over the past decade, advances in endoscopic technology have resulted in better characterization of the causes of gastrointestinal bleeding, and the ability to perform endoscopic therapy has revolutionized the approach to diagnosis and management. These improvements in diagnosis and treatment should be reflected in better outcomes, including a reduction in rebleeding rate, urgent surgical intervention, and mortality.
Indeed, endoscopic therapy for peptic ulcer bleeding has been shown to decrease rebleeding, transfusion requirements, and need for surgery. 6 Despite these advancements, however, the mortality rate of UGI bleeding has been reported to be approximately 10% and unchanged over the last several decades. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] With regard to LGI bleeding, few recent prospective studies have evaluated the causes and outcome of a large cohort of unselected patients. 5, 17, 18 To better characterize current trends in acute gastrointestinal bleeding, we report our prospective experience evaluating the cause, outcome, and variables affecting mortality in a large cohort of patients with acute upper or lower GI bleeding treated at a large academic community hospital. county hospital serving primarily the indigent population of metropolitan Atlanta, Georgia. Consecutive patients seen by the Emor y University gastroenterology consultative service and admitted for treatment of GI bleeding during this period were included. The study was approved by the Emory University Human Investigations Committee, and written informed consent was given by the patients for all endoscopic procedures.
Patients with UGI bleeding are admitted to the medical service where gastroenterology consultation is routine. Patients with LGI bleeding are usually, but not exclusively, admitted to the surgical service where gastroenterology consultation is also usually sought. Thus, our cohort does not represent all patients admitted to our institution with acute gastrointestinal bleeding. Patients assessed for GI bleeding that occurred while they were hospitalized were excluded, since these patients have a worse prognosis than patients admitted for bleeding. 19, 20 Bleeding was defined using previously published criteria. 21 Briefly, UGI bleeding was defined as follows: hematemesis and a subnormal hematocrit value or a decrease in hematocrit ≥ 5 points of the most recently documented value (by review of computerized laborator y records) within 12 to 24 hours of the time the patient was first seen in the emergency department; for patients who had melena and/or hematochezia without hematemesis or a nasogastric aspirate positive for blood ("coffee ground" material, frank blood), a causative lesion was identified proximal to the ligament of Treitz by endoscopy, barium upper GI series, surgery, or autopsy, in combination with the hematocrit changes described. Endoscopic therapy was done in standard fashion with injection of either absolute alcohol or epinephrine or with thermal coagulation using the heater probe (Olympus Corp, Lake Success, NY). However, since there was no specific protocol for endoscopic therapy during the study period, the specific endoscopic technique was up to the attending gastroenterologist. Endoscopic lesions that were routinely treated were those actively bleeding (oozing, spurting) and esophageal varices if considered the cause of bleeding. Treatment of visible vessels was individualized. Vascular ectasias were treated using the heater probe.
Lower gastrointestinal bleeding was defined as the passage of bright red blood per rectum or maroon stool without hematemesis or a bloody nasogastric aspirate and a subnormal hematocrit value (< 40%) or a decrease in hematocrit of ≥5 points of the most recently documented value within 12 to 24 hours of the time the patient was first seen in the emergency department, and a lesion considered responsible for bleeding identified distal to the ligament of Treitz by barium enema examination, colonoscopy, angiography, surgery, or autopsy. Many patients with LGI bleeding had endoscopic examination of the upper gastrointestinal tract as part of another protocol. The use of nonsteroidal anti-inflammator y drugs (NSAIDs) or aspirin (ASA) preparations Vital signs were those recorded on admission. (10) *Acute gastric mucosal lesions defined as gastric subepithelial hemorrhages and/or erosions.
†Includes esophageal cancer (6), tear (6), idiopathic ulcer (6), cytomegalovirus esophagitis (1), gastric vascular ectasias (13), varices (10), cancer (8) , syphylitic gastritis (3), Kaposi's sarcoma (2), arteriovenous malformation (2), foreign body trauma (2), duodenitis (11), vascular ectasias (2), and efferent limb ulcer at Billroth II anastomosis (3). available in our area was assessed as previously described. 22, 23 Prescription drug use at Grady Memorial Hospital was validated by review of computerized hospital pharmacy records. All endoscopic examinations were done by gastroenterology trainees with supervision by an experienced gastroenterology attending physician; all procedures were either done or supervised by (or the findings discussed with) the principal investigator (C.M.W.). For patients seen on multiple occasions during the study period, only the most severe bleeding episode (as determined by mortality, transfusion requirements, or use of endoscopic therapy) was entered in the analysis. Patients were followed up in the hospital until discharge. Rebleeding was defined as recurrent hematemesis, melena, or hematochezia occurring after initial stabilization associated with a fall in hematocrit (when obtained). Endoscopic stigmata were classified according to standard criteria. 24 
Data Management and Analysis
All patients had a number of clinical parameters recorded at the time of admission on a standardized data collection form. These variables included general demographics such as alcohol and tobacco use, history of GI bleeding, comorbid conditions, clinical presentation, stool color, endoscopic findings including stigmata, use of ancillary tests to identify the cause or to control bleeding, use of endoscopic therapy, total transfusion requirements, and hospital mortality. The data were then edited and entered via double entry verification into an analytic database. Additional quality control procedures, database management, and all statistical analyses were done using SAS software. 25 Standard descriptive statistics, including means, medians, standard deviations, and interquartile ranges, were used to separately characterize each of the UGI bleeding and LGI bleeding groups. Univariate associations among categorical variables were compared via contingency table analysis, including chisquare tests and Fisher's Exact Tests. Comparison of continuous measures between two groups were done using t tests or rank sum tests, as appropriate. Multivariate assessment of predictors of dichotomous outcomes, such as rebleeding, death, and surgery, was done using logistic regression. Covariates considered as predictors in the multivariate analyses included those found to have a univariate association with the outcome measure, as well as those previously reported in the literature. Reported P values were unadjusted for the number of comparisons, but conclusions regarding associations were based on adjustment for this multiplicity.
RESULTS

Upper Gastrointestinal Bleeding
Over the 50-month study period, 796 patients who had UGI bleeding and met the inclusion criteria were evaluated, and 727 (91%) of them had diagnostic endoscopic examination (Table 1) . Twenty-eight patients (4%) lacked a specific diagnosis, since either no evaluation was done (n = 21) or results of UGI barium study and/or endoscopy were normal or nondiagnostic. The median age of our cohort was 49 years. Endoscopy was done within 24 hours of admission in 360 patients (50%) and within 48 hours in 520 (72%). Consistent with our patient population, the Vital signs were those recorded on admission.
majority of our patients were black and used alcohol and tobacco. Comorbidity (eg, coronary artery disease, chronic lung disease, cancer) was uncommon, the most common underlying illness being hypertension. Of the patients taking NSAIDs, 334 (46%) used ASA, 174 (24%) nonaspirin NSAIDs (NANSAIDs), and 73 (10%) both. Over-the-counter ASA and NANSAIDs were used by 284 patients (39%) and 87 (12%), respectively. The causes of UGI bleeding are listed in Table 2 . Peptic ulcer disease was the most commonly identified cause. Only 49 patients had diffuse gastric subepithelial hemorrhage believed to be the cause of bleeding, which included syphilis in 1 patient and alcohol in 3. 21 Stigmata of recent hemorrhage lesions not related to portal hypertension were identified in 72% of lesions at the time of endoscopy. A visible vessel or active bleeding was identified in 6% and 10% of ulcers, respectively. Endoscopic therapy was done in 90 patients (19.6%).
Important outcome variables for UGI bleeding are shown in Table 3 . Rebleeding occurred within 1 day in 33 patients (29%) and within 2 days in 58 (52%). The rebleeding rates for ulcers with a clean base, spots/dots, and clots were 6%, 9%, and 31%, respectively. Twenty-five patients (32%) with varices had rebleeding, including 20 with esophageal varices and 5 (50%) with gastric varices. Transfusion requirements differed between patients with variceal bleeding and those with nonvariceal bleeding (6.7 units vs 4.1 units; P = .0009). Of the patients receiving endoscopic therapy at the time of initial endoscopy, 42 (30%) had recurrent bleeding (30% ulcer, 32% varices). Surgical intervention to control bleeding was infrequently necessary. In nonvariceal bleeding, recurrent bleeding was related to ulcer size and presence of hypotension on admission and was associated with requirement for surgery and with mortality. Bleeding stigmata were not associated with recurrent bleeding, likely because endoscopic therapy was used at the time of the initial endoscopy in some patients with high-risk lesions. Of the patients with recurrent nonvariceal bleeding, endoscopic therapy resulted in permanent hemostasis in 71 (87%), with 17 ultimately requiring surgery.
Although the overall mortality rate was 8.8%, significant differences were detected according to the cause of bleeding. The mortality was 2.4% among patients with MalloryWeiss tear and 4.3% among those with peptic ulcer bleeding, including gastric ulcer (4.2%) and duodenal ulcer (4.3%). The mortality associated with portal hypertension-related bleeding was 32% (esophageal varices, 32%; gastric varices, 50%; portal hypertensive gastropathy, 23%). Multivariate analysis identified portal hypertension (OR 6.2, 95% CI = 3.1 to 12.7) and rebleeding (OR 22.7, 95% CI = 11.9 to 43.5) as the only independent predictors of mortality in UGI bleeding.
Lower Gastrointestinal Bleeding
During the study period, 165 patients met the inclusion criteria for LGI bleeding (Table  4) . In contrast to patients with UGI bleeding, those with LGI bleeding were older (P<.001), more likely to be female (P<.001), and more likely to be black (P=.017). The use of NSAIDs was similar to that in patients with UGI bleeding, but alcohol consumption and tobacco use were less frequent (both, P<.001). Of the patients using NSAIDs, 48 (29%) were taking prescription NSAIDs and 44 (27%) over-thecounter NSAIDs (35 ASA and 9 NANSAIDs). Comorbid illness was present in 141 patients (85%), most commonly hypertension (101 [66%]), and diabetes mellitus (33 [20%] ). Compared with patients having UGI bleeding, those with LGI bleeding were significantly *Includes: cytomegalovirus colitis (1), postpolypectomy (1), arteriovenous malformation (1), ileal hematoma (2), pancreatic pseudoaneurysm (1), and jejunal vascular ectasia (2). more likely to have underlying hypertension (P =.001), diabetes mellitus (P =.03), coronary artery disease (P =.006), and peripheral/cerebrovascular disease (P =.01). The causes of LGI bleeding are outlined in Table 5 . Colonoscopy was done in all but 15 patients, and 112 patients (68%) had upper endoscopy. The diagnosis was established by surgery in 1 patient, angiography in 1, and barium enema in 2 patients. Five patients had no diagnosis established because they refused evaluation. Colonoscopy was done within 24 hours in 31 patients (21%) and within 48 hours in 57 (38%). In 8 patients, bleeding was considered to be from the small bowel, though the precise cause of bleeding was not established endoscopically or radiographically; these patients had normal findings on upper and lower endoscopy.
The outcomes of LGI bleeding are listed in Table 6 . In contrast to cases of UGI bleeding, endoscopic therapy was rarely done, being used in only 2 patients. One patient had heater probe ablation of bleeding cecal vascular ectasias, and the other had epinephrine injection of a bleeding polypectomy site. One patient had angiographic embolization of a bleeding diverticulum, resulting in permanent hemostasis. Overall, rebleeding was observed in 33 patients (20%) and occurred within 24 hours in 7 (21%) and within 48 hours in 15 (45%). Diverticular rebleeding was observed in 15 patients (27%) and occurred within 24 hours in 3 (20%) and within 48 hours in 7 (47%). The overall transfusion requirements, need for surgery to control bleeding, and mortality were not significantly different with regard to the cause of bleeding (data not shown). Because only six deaths occurred, power was limited in evaluating for factors associated with mortality from LGI bleeding.
DISCUSSION
Our large prospective study documents the spectrum of causes and examines the outcome of both upper and lower GI bleeding evaluated at a community-based academic nontertiary medical center. Consistent with previous reports, 2,4,5 peptic ulcer disease and diverticulosis were the most common causes of UGI bleeding and LGI bleeding, respectively. We found that the overall mortality rates for these two groups was low. Our patients with nonvariceal UGI bleeding had a low mortality rate, and surgery was rarely necessary to control bleeding. The rebleeding rate and overall mortality for LGI bleeding was also lower than in earlier studies, 33, 35, 39, 46 particularly for diverticular bleeding, and surgical therapy was also rarely required to control hemorrhage.
The causes of UGI bleeding in our study are similar to those reported in recent studies. 2, 4, 15, 17, 26 In contrast to earlier studies, however, we found a low prevalence of gastritis as a cause. In addition, although NSAID use was common, ulcer was the most common cause of bleeding in patients using these medications. As suggested by others, 26 our data further support the notion that gastritis has been an overemphasized cause of UGI bleeding.
The mortality of UGI bleeding has been said to be unchanged over the past 5 decades and remains at 10%. 8 However, we found the overall death rate to be low and similar to that in some recent reports. [2] [3] [4] When stratifying outcome based on cause, important differences were also found. The mortality rate for peptic ulcer bleeding was only 4%, which is in striking contrast to the 32% mortality rate among patients with esophageal or gastric variceal hemorrhage. This high mortality for portal hypertension-related bleeding is well recognized. [27] [28] [29] The reason(s) for our low mortality from nonvariceal bleeding is unknown. The relatively young age of our patients may be one explanation, since 50% of the deaths occurred in patients older than 50 years. Likewise, comorbid illness was also infrequent. Previous studies have identified older age (usually >60 years) and comorbidity as important prognostic factors in UGI bleeding. 2, 12, [14] [15] [16] [17] The use of endoscopic therapy may perhaps be an explanation for improved sur vival. Although the cause of death was not recorded for each patient, our experience suggests that bleeding was rarely the cause of death in patients with nonvariceal bleeding, in contrast to those with portal hypertension. Indeed, the factors that we identified as predictors of mortality in UGI bleeding, which included portal hypertension and rebleeding, have been previously identified. [30] [31] [32] Our large study suggests that the overall mortality and outcome in cases of nonvariceal UGI bleeding managed in a community setting may be improving.
Recent studies of LGI bleeding have focused primarily on the rapid diagnosis of severe bleeding. [33] [34] [35] The identified causes of bleeding were similar to those in other reports that included all patients with LGI bleeding. 5, 18, [33] [34] [35] [36] [37] In most 5, 17, 18, 34, 36 but not all 33 of these studies, diverticulosis was the most common bleeding source, ranging in prevalence from 19% to 57%. As with other studies, 5,18,37 we found vascular ectasias to be an uncommon cause of bleeding (<10% of cases). A surprising finding of our study was the prevalence of colonic ulcers as a cause of LGI bleeding. The high prevalence of colonic ulcers identified in our study might reflect some unique but unrecognized biases in our institution or possibly the high prevalence of NSAID use, which has been linked to colonic ulceration. 38 Few recent prospective studies have examined the outcome of a consecutive series of patients with LGI bleeding. We found the overall mortality rate to be low, despite the age of our patients and frequent comorbidity. Previous reports have shown mortality rates that ranged from 0% to 21%. 5, 17, 18, [39] [40] [41] Some of these studies were biased toward patients with more severe bleeding, considering their greater transfusion requirements, a focus exclusively on diverticular disease, 38 or use of colonoscopy to evaluate and treat severe bleeding. [33] [34] [35] The need for surgery was also low in our study compared with other reports; these differences in use of surgical therapy likely reflect bias from surgical series.
CONCLUSION
Our large prospective study documents the wide spectrum of causes of GI bleeding. The causes of bleeding appear to be little changed from those reported in studies over the past several decades, with the exception that gastritis has been a previously overemphasized cause of UGI bleeding. Despite claims that the mortality rate for GI hemorrhage remains unchanged, we identified a low overall mortality among patients with both upper and lower GI bleeding. This favorable mortality perhaps could be a reflection of improved diagnosis and more frequent use of effective endoscopic therapy.
